AngioDynamics, Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for AngioDynamics, Inc., covering the three and nine months ended February 28, 2011. The company designs, develops, and markets medical devices for minimally invasive procedures, primarily in peripheral vascular disease and oncology. Effective June 1, 2010, the company reorganized its reporting segments into two divisions: Vascular (combining Peripheral Vascular and Access) and Oncology/Surgery.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Feb 28, 2011 | 9 Months Ended Feb 28, 2011 |
|---|---|---|
| Net Sales | $54,648 | $159,527 |
| Gross Profit | $31,721 (58.0%) | $93,277 (58.5%) |
| Operating Income | $5,248 (9.6%) | $14,126 (8.9%) |
| Net Income | $3,811 | $8,978 |
| Diluted EPS | $0.15 | $0.36 |
| Cash & Marketable Securities | $120,230 (as of Feb 28, 2011) | N/A |
| Total Debt | $6,615 (Current + Long-term) | N/A |
| Operating Cash Flow | N/A | $21,973 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.7% for the quarter and 2.4% for the nine-month period compared to the prior year. Growth was driven by increased unit sales of LC Beads, NanoKnife products, and vascular access ports, partially offset by a 3-6% decline in average selling prices in the Vascular segment.
- Segment Performance: Vascular sales decreased slightly in the quarter (-0.4%) and by 3.3% year-to-date due to price erosion and lower dialysis product sales. Conversely, Oncology/Surgery sales grew 19% in both periods, driven by NanoKnife and LC Bead volume.
- Profitability: Operating income margin declined from 10.7% to 9.6% in the quarter and from 9.3% to 8.9% year-to-date. This was primarily due to increased R&D spending (up 24% in the quarter) and higher G&A expenses related to facility expansion and severance costs.
- Tax Rate: The effective tax rate decreased significantly to 25% for the quarter and 32% year-to-date (from 38% in prior periods) due to the retroactive renewal of the R&D tax credit and an increase in the Domestic Production Activities Deduction.
Outlook, Risks, and Unusual Items
- Regulatory Action: On January 24, 2011, the company received an FDA Warning Letter regarding the marketing of the NanoKnife System, alleging promotion beyond cleared indications. While the letter does not prohibit sales, the company faces potential additional regulatory action or fines if the FDA is not satisfied with their response.
- Impairment Risk: Management is evaluating the Vascular product strategy. If the company decides not to further develop the Medron technology, an impairment charge of up to $4.2 million (net book value) could be recorded, which would be material to results of operations.
- Litigation: Ongoing litigation with biolitec, Inc. involves cross-claims for defense costs totaling approximately $1.6 million. The company believes the outcome will not have a material adverse effect.
- Liquidity: The company holds $120.2 million in cash and marketable securities. However, $1.85 million is invested in auction rate securities that have failed auctions, creating potential liquidity constraints for those specific assets.
- Guidance: The company expects R&D expenditures to remain between 8% and 10% of net sales for fiscal 2011, driven by NanoKnife technology investment.
Investor Verification Checklist
- Verify the status of the FDA Warning Letter response and any potential impact on NanoKnife sales or marketing restrictions.
- Monitor the outcome of the Medron technology evaluation for potential impairment charges up to $4.2 million.
- Review the expiration of the LC Bead distribution agreement (December 31, 2011) and the risk of non-renewal following the acquisition of Biocompatibles by BTG PLC.
- Assess the liquidity risk associated with the $1.85 million in failed auction rate securities.
- Track the resolution of the biolitec litigation regarding the $1.6 million counter-claim.